The table below shows RECURSION PHARMACEUTICALS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$81.10M
-$131.96M
-$102.30M
-$73.32M
$77.39M
-$30.75M
Capital expenditure
$258.00K
$1.83M
$6.65M
$5.17M
$4.34M
$19.42M
Investing cash flow
-$338.00K
-$7.27M
-$6.65M
-$5.34M
$143.30M
-$19.42M
Dividends paid
-
-
-
RXRX operating cash flow (10-K history)
RECURSION PHARMACEUTICALS, INC. reported operating cash flow of -$371.81M for fiscal year 2025. That is down 3.5% from -$359.17M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$57.04M (FY 2019) to -$371.81M. Figures come from the company's audited annual reports as filed with the SEC.
